Job Trends
Rampart Bioscience was working on a platform to deliver gene therapies without the need for viral vectors.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.
Job listings in the area have ticked up in the last month. These seven companies are hiring in South San Francisco right now, including scientist and clinical roles.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Career Advice
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.
THE LATEST
Ra Medical only has five full-time salespeople on staff, but expects that to grow to 20 to 25 people later this year.
The news was disclosed by Ruyi He, MD, Chief Scientist of the CFDA and the Center for Drug Evaluation.
Changes are coming to Medtronic.
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference.
GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.
Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years.
GlaxoSmithKline CEO Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division.
Since the acquisition fell apart, Allergan has fallen on some hard times.
The Phase II part of the trial is underway with patients who had select solid tumors with 0-2 prior lines of systemic therapy.
The company said it will acquire Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis.